Wegovy vs Ozempic: Same Semaglutide, Two Labels

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub: clear, evidence-based GLP-1 comparisons anchored to the genetics behind metabolic response. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Novo Nordisk.

Here is the twist that trips up most Wegovy-versus-Ozempic searches: they are the same active molecule, semaglutide, sold under two brand names for two different labels. The real differences are dose, indication, price, and coverage — not chemistry. This review lays out where they actually diverge as of April 2026, then closes on the genetics that apply no matter which label you fill.

Same molecule, two brand names

Wegovy is a selective glucagon-like peptide-1 (GLP-1) receptor agonist from Novo Nordisk. Ozempic is a selective glucagon-like peptide-1 (GLP-1) receptor agonist, also from Novo Nordisk. Both are semaglutide and both engage the GLP-1 receptor across the pancreas, hypothalamus, and gut — slowing gastric emptying, blunting post-meal glucose, and increasing satiety. By contrast, tirzepatide-based compounds add GIP-receptor agonism, which these two do not.

Dose and indication, not chemistry

Wegovy is FDA-approved for chronic weight management (2021) in adults with BMI ≥ 30, or ≥ 27 with at least one weight-related condition. Ozempic is FDA-approved for type 2 diabetes (2017), with the same active ingredient widely studied for weight management. The label and the dose — not a different molecule — are what separate these two brand names in practice, and they drive coverage.

STEP and SUSTAIN: the two evidence tracks

Wegovy was evaluated in the STEP program (chronic weight management), while Ozempic was evaluated in the SUSTAIN program (cardiovascular and glycemic outcomes). Some comparisons are indirect — the SURMOUNT and STEP programs have been compared indirectly — and SURPASS evaluated tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Because populations and endpoints differ, each program answers its own question rather than settling a single ranking.

Side effects when the active ingredient is identical

Because both are semaglutide, tolerability tracks closely. Both carry the GLP-1 class boxed warning tied to thyroid C-cell tumor risk observed in rodent studies. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually most pronounced during dose escalation. Serious adverse events reported across the class include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

Why the price and coverage differ

Wegovy's U.S. list price is approximately $1,349 per month as of April 2026 (Novo Nordisk published pricing). Ozempic's U.S. list price is approximately $968–$1,029 per month as of April 2026 (Novo Nordisk published pricing). Out-of-pocket cost depends heavily on insurance coverage, manufacturer savings cards, the specific FDA indication on the prescription, and whether a compounded alternative is available through a licensed compounding pathway.

The genetics that don't care which label you fill

Since both brands deliver the same molecule, the upstream genetics are identical either way. Variants in FTO (fat-mass and obesity-associated gene; appetite and adiposity set-point), GLP1R (encodes the GLP-1 receptor semaglutide engages), MC4R (melanocortin receptor central to energy balance), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) shape baseline biology. These are pathway-level markers; they do not predict response to Wegovy, Ozempic, or any single compound.

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide Injection protocol. The differentiator is upstream genetic context. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline biology. That is the test before you invest approach.

Related reading on PlexusDx: Ozempic Injection, Ozempic 25 Coupon, Ozempic and Weight Loss, Ozempic Near Me.

Disclaimer: This is educational content. PlexusDx offers semaglutide through its Weight Management Protocols; this article covers the mechanism, evidence, and genetic context informing any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats in the Weight Management Protocols collection, or start upstream with the Precision Peptide Genetic Test.

Frequently Asked Questions

Are Wegovy and Ozempic literally the same drug?

Both contain semaglutide and are made by Novo Nordisk, so the active molecule is the same. They differ in FDA-approved indication and dosing — Wegovy is labeled for chronic weight management, Ozempic for type 2 diabetes — which is what separates the two brand names in everyday use.

If the molecule is identical, why compare them at all?

Because label, dose, price, and insurance coverage differ, the practical experience of getting and paying for each can vary considerably. The pharmacology overlaps, but access does not, so comparing indication and cost is more useful than comparing the underlying chemistry, which is essentially the same.

Does the genetic test favor one brand?

No. The Precision Peptide Genetic Test does not predict response to Wegovy, Ozempic, or any medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 biology — context that is identical for both brands because both deliver the same semaglutide molecule.

Will side effects feel different between them?

Because both are semaglutide, tolerability is broadly comparable, with gastrointestinal symptoms most common during dose escalation. Both carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies. Dose differences can influence the experience, so discuss titration and history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.